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ABSTRACT 
Objective: Ivabradine (IB) is anti-Ischemic drug and used for the symptomatic management of stable angina pectoris. IB acts by reducing the heart 
rate in a mechanism different from beta blockers and calcium channel blockers, two commonly prescribed anti-anginal drugs. IB has a short 
biological half-life and the dose of 5/7.5 mg twice a day. In this present study, an attempt has been made to prepare sustained release tablet of IB to 
achieve the desired drug release.  
Methods: The sustained release polymers, hydroxypropyl methylcellulose K100M (HPMC K100M), guar gum (GG) and xanthan gum (XG) were 
taken for the preliminary trail from which guar gum and xanthan gum had shown better drug release. Initially, drug-excipients compatibility studies 
were carried out by using Fourier transformed infrared spectroscopy (FTIR) and Differential Scanning Calorimetry (DSC) which showed no 
interaction between drug and excipients. Tablets were prepared by wet granulation technique and evaluated for pre-compression and post-
compression parameters.  
Results: 32 full factorial design was applied to achieve controlled drug release up to 24 h. The concentration of GG (X1) and XG (X2) were selected as 
independent variables and the % CDR at 2 h. (Y1) and 18 h. (Y2) were taken as dependent variables. In vitro drug release study revealed that as the 
amount of polymers increased, % CDR decreased.  
Conclusion: Contour as well as response surface plots were constructed to show the effect of X1 and X2 on % CDR and predicted at the 
concentration of independent variables X1 (10 mg) and X2 (10 mg) for a maximized response. The optimized batch (O1) was kept for stability study 
at 40±2 °C/75±5 %RH for a period of 6mo according to ICH guidelines and found to be stable. 
Keywords: Sustained release matrix tablet, IB, Guar gum, Xanthan gum, 32 full factorial design 




To formulate an API in an extended drug delivery system is related to its 
pharmacokinetics parameters. An appropriate formulation can make the 
absorption, distribution, metabolism and elimination (ADME) profile of a 
drug much more favorable. It is designed to maintain constant levels of a 
drug in the patient’s bloodstream by releasing the drug over an extended 
period. Maintaining constant blood levels of the drug in the bloodstream 
increases the therapeutic effectiveness of the drug. The sustained release 
drug delivery system provides the sustained and continuous oral 
delivery of drugs at predictable and reproducible kinetics for a 
predetermined period throughout the course of GI transit and also the 
system that targets the delivery of a drug to a specific region within the 
GI tract for either a local or systemic effect. The change of the ADME can 
have a profound impact on many aspects of the clinical use of the drug 
from patient compliance and convenience to its very efficacy, tolerance 
and safety parameters [1]. 
IB is If channel antagonist used in the treatment of angina pectoris 
which is an underlying cause of heart attack when beta blockers are 
not responding. IB is rapidly and almost completely absorbed after 
oral administration with a peak plasma level reached in about 1 h 
under fasting condition. It has a plasma half-life about (2 h) and 
bioavailability is 40% orally, due to the first-pass effect in the gut 
and liver. The short biological half-life and dosing frequency of IB 
make it an ideal candidate for sustained release tablet [2]. 
The objective of the present study was to prepare and evaluate IB 
sustained release tablet, in order to improve its reducing dose 
frequency, bioavailability and efficacy. 
MATERIALS AND METHODS 
IB was gifted from Torrent Pharmaceuticals, Ahmedabad. XG, 
lactose, GG, starch, magnesium stearate and talc were purchased 
from SD Fine Chemicals, Mumbai, India. All other chemicals and 
solvents used were of the pharmaceutical and analytical grade. 
Double distilled water was used throughout the study for 
experimental work. 
Drug-excipient compatibility studies by DSC 
The possibility of drug–excipient interaction was investigated by 
DSC. It allows the fast evaluation of possible incompatibilities 
because it shows changes in appearance, shift or disappearance of 
melting endotherms and exotherms, and/or variations in the 
corresponding enthalpies of reaction. The DSC thermograms of pure 
drug, a mixture of the drug with GG and XG, starch and lactose were 
recorded. The samples were separately sealed in aluminium cells 
and set in a DSC-60 instrument (Shimadzu Corporation, Tokyo, 
Japan). The thermal analysis was performed in a nitrogen 
atmosphere at a heating rate of 20 °C/min over a temperature range 
of 50 to 300 °C [3-4]. 
32 full factorial design 
A 32 full factorial design was employed to systematically study the 
joint influence of the effect of independent variable concentration of 
GG (X1) and XG (X2) on the dependent variable, i.e. % CDR at 2 h (Y1) 
and % CDR at 18 h (Y2) (table 1). In this design, 2 factors were 
evaluated, each at 3 levels, and experimental trials are performed in 
all 9 possible combinations. A statistical model incorporating 
interactive and polynomial terms is used to evaluate the response. 
Polynomial equation generated by this design is as follows:  
Y =b0+b1X1+b2X2+b12X1X2+b11X12+b22X22 
Where Y is the dependent variable, b0 is the arithmetic mean 
response of the 9 runs, and b1 to b2 are the regression coefficients. 
The main effects (X1 and X2) represent the average result of changing 
1 factor at a time from its low to high value. The interaction terms 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 10, Issue 1, 2018 
Patel et al. 
Int J App Pharm, Vol 10, Issue 1, 2018, 59-66 
 
60 
(X1X2) show how the response changes when two factors are 
simultaneously changed. The polynomial terms (X12 and X22) are 
included to investigate nonlinearity.  
The response values are subjected to MLRA (Multiple linear 
regression analysis) to find out the relationship between the factors 
used and response values obtained. After application of full factorial 
design and with the help of produced polynomial terms, amount of 
formulation variable was optimized [5-7]. 
Preparation of sustained-release tablets 
The matrix tablets, with a theoretical weight of 200 mg, containing 
IB together with other excipients were prepared by wet 
granulation technique. IB and other excipients are weighed 
accurately, transferred in mortar and pestle and thoroughly mixed 
for 15 min. The powder mixture was granulated with 10%w/v 
starch paste. The wet mass was passed through 10# sieve and 
granules were dried at 50 °C for 30 min in a hot air oven. The dried 
granules were passed through a 20# sieve and lubricated with talc 
and magnesium stearate which was previously passed through an 
80# sieve. Tablets were compressed using 6 mm punch on 10 
stations rotary tablet punching machine (Karnavati Engineering). 
The hardness of the tablets was maintained between 5.0 to 6.0 
kg/cm2. The detailed compositions of the prepared sustained 
release tablet formulations are given in table 2 [8]. 
 
Table 1: Selection of levels for independent variables and coding of variable 
Levels Coded value Independent variables 
Concentration of GG (mg) X1 Concentration of XG (mg) X2 
Low -1 10 10 
Intermediate 0 20 20 
High +1 30 30 
GG–guar gum, XG–xanthan gum 
 
Table 2: Composition of factorial design batches 
Ingredients (mg) O1 O2 O3 O4 O5 O6 O7 O8 O9 
IB 15 15 15 15 15 15 15 15 15 
GG 10 20 30 10 20 30 10 20 30 
XG 10 10 10 20 20 20 30 30 30 
Lactose 160 150 140 150 140 130 140 130 120 
MS 3 3 3 3 3 3 3 3 3 
Talc 2 2 2 2 2 2 2 2 2 
Total weight (mg/tablet) 200 200 200 200 200 200 200 200 200 
IB–ivabradine, GG–guar gum, XG–xanthan gum, MS–magnesium stearate 
 
Evaluation parameters of sustained-release tablets 
Pre-compression evaluations 
Bulk density (BD) 
Weigh accurately 10 g of powder, which was previously passed 
through a 20# sieve and transferred into 100 ml graduated cylinder. 
Carefully level the powder without compacting, and read the 
unsettled apparent volume. Calculate the apparent bulk density in 
g/cm3 by the following formula [9]. 
 
Tapped density (TD) 
Weigh accurately 10 g of powder, which was previously passed 
through a 20# sieve and transfer in 100 ml graduated cylinder. Then 
mechanically tap the cylinder containing the sample by raising the 
cylinder and allowing it to drop under its own weight using 
mechanically tapped density tester that provides a fixed drop of 
14±2 mm at a nominal rate of 300 drops per minute. Tap the 
cylinder for 500 times initially and measure the tapped volume (V1) 
to the nearest graduated units, repeat the tapping an additional 750 
times and measure the tapped volume (V2) to the nearest graduated 
units. If the difference between the two volumes is less than 2%, 
then final the volume (V2). Calculate the tapped density in g/cm3 by 
the following formula [9]. 
 
Carr’s index 
Compressibility index is used as an important parameter to 
determine the flow behaviour of the granules. It is indirectly related 
to the relative flow property rate, cohesiveness and particle size. It is 
simple, fast and popular method for predicting flow characteristics. 
Carr’s index can be represented by the equation [10]: 
 
Hausner’s ratio 
Hausner’s ratio is used to predict the flowability of the granules. 
This method is similar to compressibility index. Hausner’s ratio can 
be represented by an equation as shown below [10]: 
 
Angle of repose 
The angle of repose of powder was determined by the funnel 
method. The accurately weight powder blend was taken in the 
funnel. The height of the funnel was adjusted in such a way that the 
tip of the funnel just touched the apex of the powder blend. The 
powder blend was allowed to flow through the funnel freely onto the 
surface. The diameter of the powder cone was measured and angle 
of repose was calculated using the following equation [10].  
Ө = tan-1 h/r 
Post-compression evaluations 
Weight variation 
Uniformity of weight as described in the United States Pharmacopeia 
(USP) was followed. Twenty tablets were selected at random and 
average weight was determined. Then individual tablets were 
weighed and the individual weight was compared with the average 
weight. The percentage deviation was calculated and checked for 
weight variation. Using this procedure weight variation range of all 
batches of formulations were determined and recorded [11]. 
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The thickness of three tablets was measured using vernier callipers. 
The extent to which the thickness of each tablet deviated from±5% 
of the standard value was determined [11]. 
Hardness 
The hardness of the tablet was determined by Monsanto hardness 
tester. Three tablets from each batch were selected and evaluated, 
and the average value with standard deviation was recorded [11]. 
Friability 
Friability of tablets was performed in a Roche friabilator. Five tablets 
were weighed together and then placed in the chamber. The friabilator 
was operated for 100 revolutions and the tablets were subjected to the 
combined effects of abrasion and shock because the plastic chamber 
carrying the tablets drops them at a distance of six inches with every 
revolution. The tablets are then dusted and re-weighed [11]. 
 
Drug content 
The drug content was carried out by weighing ten tablets from each 
batch and calculated the average weight. Then the tablets were 
triturated to get a fine powder. From the resulting triturate, the powder 
was weighed accurately which was equivalent to the specified weight of 
IB and dissolved in 100 ml volumetric flask containing 100 ml of pH 6.8 
phosphate buffer and volume was made up to 100 ml with phosphate 
buffer. The volumetric flask was shaken using a sonicator for 1 h and 
after suitable dilution with pH 6.8 phosphate buffer, the drug content 
was determined using UV-visible spectrophotometer at 277.60 nm [12]. 
In vitro drug release study 
The release of the prepared tablets was determined using U. S. P-
type II paddle type dissolution rate test apparatus (TDT-06P, 
Electrolab) using 900 ml of pH 6.8 phosphate buffer as dissolution 
medium. The paddle was adjusted at 50 RPM and the temperature of 
37±1 °C was maintained throughout the experiment. Withdrawn not 
less than 5 ml of the dissolution medium at 1, 2, 4, 8, 12, 18, 20, 24 h 
time interval up to 24 h and were replaced with the same volume of 
fresh dissolution media after each withdrawal. Filtered each sample 
through a membrane filter with a pore size of not more than 0.45 
mm. The samples were analysed after appropriate dilution by UV 
spectrophotometer at λ max 277.60 nm [13-14]. 
Statistical analysis 
Statistical analysis of the 32 factorial design batches was performed 
by MLRA using Microsoft excel. In this design 2 factors are 
evaluated, each at 3 levels, and experimental trials are performed at 
all 9 possible combinations. To evaluate the contribution of each 
factor with different levels to the response, the two-way analysis of 
variance (ANOVA) was performed using the design expert 10.0.6.0 
(STAT–EASE) demo version software. To graphically demonstrate 
the influence of each factor on the response, the response surface 
plots, the normal plot of residual, two-dimensional counterplot, 3-D 
graph, and overlay plot, were generated using the design expert 
10.0.6.0 (STAT–EASE) demo version software [3, 15-16]. 
Checkpoint analysis 
A checkpoint analysis was performed to confirm the role of the derived 
polynomial equation and contour plots in predicting the responses. 
Values of independent variables were taken at 3 points and the 
theoretical values of % CDR at 2 h and %CDR at 18 h were calculated by 
substituting the values in the polynomial equation [3, 15-16]. 
Optimization of formulation 
The computation for optimized formulation was carried using design 
expert 10.0.6.0 (STAT–EASE) software. The optimized formulation was 
obtained by applying constraints (goals) on the dependent (response) 
and independent variables (factors). The models were evaluated in 
terms of statistically significant coefficients and R2 values. Various 
feasibility and grid searches were conducted to find the optimum 
parameters. Various 3D response surface graphs were provided by the 
design expert software. The optimized formulation factors were 
evaluated for various response properties [3, 17-18]. 
Kinetics of drug release 
In order to describe the kinetics of drug release from sustained 
release formulation, various mathematical equations have been 
proposed, namely zero order, first order, higuchi model and hixson–
crowell cube root law. To authenticate the release model, dissolution 
data can further be analyzed by Korsmeyer Peppas equation.  The 
criteria for the selection of most suitable model were the value of 
regression coefficient (R2) nearer to 1, smallest values of Residual 
Sum of Squares (SSR) and Akaike Information Criteria (AIC) [3, 14]. 
Stability study 
Stability studies of the optimized formulation were carried out to 
determine the effect of the presence of formulation additives on the 
stability of the drug and also to determine the physical stability of 
the formulation under accelerated storage conditions. The tablets 
were stored in an aluminium foil and subjected to elevated 
temperature and humidity conditions of 40±2 °C/75±5 % RH for a 
time period of six mo [3, 5]. 
RESULTS AND DISCUSSION 
Drug excipients compatibility study by DSC 
The DSC thermogram (fig. 1) of pure IB exhibited a sharp 
endothermic peak at 198.42 °C which corresponds to its melting and 
decomposition. Basically, IB endothermic peak was evident in all the 
thermograms of its physical mixtures with the mentioned excipients 
which might indicate compatibility. In conclusion, the observed DSC 
results ruled out the incidence of any incompatibility between IB 
and the investigated excipients. 
 
 
Fig. 1: DSC thermogram of (A) IB and (B) mixture of IB with all excipients 
Patel et al. 
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Evaluation parameters of full factorial design batches O1 to O9 
Pre-compression evaluations 
All the precompression parameters were evaluated i.e. bulk density, 
tapped density, carr’s index, hausner’s ratio, the angle of repose. 
Bulk density ranged from 0.513±0.31 to 0.654±0.45 g/cm3, tapped 
density ranged from 0.602±0.28 to 0.773±0.42 g/cm3, carr’s index 
ranged from 12.32±1.2 % to 15.39±1.25 %, hausner’s ratio ranged 
from 1.14±0.005 to 1.18±0.07 whereas angle of repose ranged from 
23.25±2.28 to 27.30±1.25.  
All these results as shown in table 3 indicated that, the powder blend 
possesses good to passable flowability and compressibility properties. 
 
Table 3: Pre-compression evaluations of batches O1 to O9 
Batch Code Bulk density (g/cm3)* Tapped density (g/cm3)* Compressibility index 
(%)* 
Hausner’s ratio* Angle of repose 
(Ө)* 
O1 0.513±0.31 0.602±0.28 14.78±1.34 1.17±0.071 23.25±2.28 
O2 0.597±0.39 0.696±0.31 14.22±1.31 1.16±0.025 26.15±1.43 
O3 0.548±0.32 0.639±0.28 14.24±1.18 1.16±0.025 25.26±1.31 
O4 0.603±0.44 0.708±0. 38 14.83±1. 85 1.17±0.011 24.15±2.27 
O5 0.559±0.53 0.654±0.49 14.52±1.27 1.16±0.05 27.30±1.25 
O6 0.654±0.45 0.773±0.42 15.39±1.25 1.18±0.07 25.32±1.25 
O7 0.612±0.32 0.698±0.28 12.32±1.2 1.14±0.015 25.30±2.15 
O8 0.632±0.25 0.726±0.21 12.94±1.26 1.14±0.005 24.30±1.15 
O9 0.579±0.41 0.668±0. 36 13.32±1.27 1.15±0.035 24.64±2.52 
*n = 3. (mean±SD) 
 
Table 4: Post-compression evaluation of batches O9 to O17 
Batch code Weight variation* Thickness (mm)# Hardness (kg/cm2)# % Friability $ % Drug content @ 
O1 Pass 3.41±0.095 5.94±0.036 0.41±0.017 99.26±1.32 
O2 Pass 3.42±0.02 5.69±0.015 0.47±0.02 98.60±1.87 
O3 Pass 3.47±0.015 5.11±0.023 0.57±0.45 99.00±0.71 
O4 Pass 3.53±0.32 5.73±0.208 0.61±0.45 99.50±1.47 
O5 Pass 3.30±0.05 5.81±0.098 0.50±0.015 99.33±1.52 
O6 Pass 3.28±0.075 5.83±0.055 0.53±0.03 98.13±2.23 
O7 Pass 3.45±0.047 5.61±0.0 58 0.43±0.15 99.45±1.18 
O8 Pass 3.60±0.041 5.48±0.03 0.63±0.04 99.86±1.52 
O9 Pass 3.20±0.037 5.48±0.018 0.61±0.03 99.40±0.36 
*n = 20, # = 3, $ = 5 and @ = 10. (mean±SD) 
 
Post-compression evaluations 
The tablets from all the batches were evaluated for various 
physical parameters before proceeding further and results are 
listed in table 4. 
Weight variation 
All the formulated batches passed the weight variation test as the % 
weight variation was within the pharmacopoeia limits of ±5% of the 
weight.  
Thickness 
The thickness of all tablets was in the range between 3.20±0.037 
mm to 3.60±0.041 mm. 
Hardness and friability 
The hardness of tablets was in the range between 5.11±0.023 to 
5.94±0.036 kg/cm2. Friability was in the range between 0.41±0.017 
to 0.63±0.4 %. Friability values were less than 1 % in all cases which 
shows good mechanical strength at the time of handling and 
transports.  
Drug content 
Drug content of all tablets was found in the range between 
98.13±2.23 to 99.86±1.52 %. This ensured the uniformity of the 
drug content in the tablets. 
In vitro drug release study 
All the formulated sustained release tablets of IB (Batches O1 to O9) 
were developed using different concentrations of GG and XG (10, 20 
and 30 mg) each and subjected to in vitro drug release study using 
pH 6.8 phosphate buffer for 24 h. Results of % CDR values are shown 
in fig. 2. From the fig., it was observed that as the concentration of 
both the polymers GG and XG increases, the amount of drug release 
decreases. The results also revealed that batch O1 containing less 
concentration of GG and XG has shown better drug release (99.82 
%). Therefore, it was considered as optimized batch among all 
formulated batches. 
Statistical analysis 
Preliminary investigations of the process parameters revealed that 
factors concentration of GG (X1) and concentration of XG (X2) highly 
influenced the rate of in vitro dissolution and, hence, were used for 
further systematic studies.  
Effect of polymers on % CDR at 2 h 
Mathematical relationships generated for the studied response 
variables concentration of GG (X1) and concentration of XG (X2) for 
%CDR at 2 h (Y1) is as follows:  
Y1 = 30.16–3.98X1-1.42X2+0.27X1X2-2.40X12+0.14X22, R2= 0.9920 
Higher values of correlation coefficients for %CDR at 2 h indicate a 
good fit. The polynomial equations can be used to draw conclusions 
after considering the magnitude of the coefficient and the 
mathematical sign it carries, i.e. positive or negative. MLRA revealed 
that coefficient b1 and b2 is negative. This indicates that on 
decreasing X1 and X2, % CDR increases.  
The lower level of X1 and of X2 was found to be favorable conditions for 
obtaining better dissolution. Table 5 shows the results of ANOVA, 
which was performed to identify insignificant factors. The coefficients 
b1, b2, and b12 were found to be significant at P is less than 0.05 and 
thus, were retained in the reduced model equation [18]. 
Y1= 30.16–3.98X1-1.42X2–2.40 X12, R2= 0.9893 
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Fig. 2: % cumulative drug release study of batches O1 to O9 (n = 6) 
 
Table 5: ANOVA response surface quadratic model for Y1 
Source SS Df MS F Value p-value prob>F 
Model 119.14 5 23.83 74.59 0.0024 
X1 95.20 1 95.20 298.02 0.0004 
X2 12.13 1 12.13 37.96 0.0086 
X1X2 0.29 1 0.29 0.90 0.4137 
X12 11.49 1 11.49 35.96 0.0093 
X22 0.038 1 0.038 0.12 0.7521 
Residual 0.96 3 0.32 - - 
Cor Total 120.10 8 - - - 
*ANOVA-analysis of variance, Df-degrees of freedom, SS-sum of squares, MS-mean of squares, F-Fischer's ratio. 








X1 = A: Conc. of Guar Gum
X2 = B: Conc. of Xanthan Gum






R1 (%CDR at 2 hr)





















Prediction  33.5719 
 
Fig. 3(a): Two-dimensional contour curve of GG (X1) and XG (X2) for %CDR at 2 h (Y1) 
 
Effect of polymers on % CDR at 18 h 
Mathematical relationships generated for the studied response 
variables concentration of GG (X1) and concentration of XG (X2) for 
%CDR at 18 h (Y2) is as follows:  
Y2 = 74.69–3.97X1–4.53X2+0.61X1X2+1.17X12+0.66X22, R2= 0.9983 
Higher values of correlation coefficients for %CDR at 18 h indicate a 
good fit. The polynomial equations can be used to draw conclusions 
after considering the magnitude of the coefficient and the 
mathematical sign it carries, i.e. positive or negative. MLRA revealed 
that coefficient b1 and b2 is negative. This indicates that on 
decreasing X1 and X2, % CDR increases. The lower level of X1 and of 
X2 was found to be favorable conditions for obtaining better 
dissolution. Table 6 shows the results of ANOVA, which was 
performed to identify insignificant factors. The coefficients b1, b2, b12, 
and b12 were found to be significant at P is less than 0.05 and thus, 
were retained in the reduced model equation [18].  
Y2= 75.12–3.97X1–4.53X2+0.61X1X2+1.165X12, R2= 0.994 
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Fig. 3(b): 3-D graph showing the effect of GG (X1) and XG (X2) for % CDR at 2 h (Y1) 
 
Table 6: ANOVA response surface quadratic model for Y2 
Source SS Df MS F Value p-value prob>F 
Model 223.17 5 44.63 371.43 0.0002 
X1 94.80 1 94.80 788.92 <0.0001 
X2 123.31 1 123.31 1026.11 <0.0001 
X1X2 1.48 1 1.48 12.28 0.0393 
X12 2.71 1 2.71 22.59 0.0177 
X22 0.87 1 0.87 7.25 0.0743 
Residual 0.36 3 0.12 - - 
Cor Total 223.53 8 - - - 
SS-sum of squares, Df-degrees of freedom, MS-mean of squares, F-Fischer's ratio. 
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Fig. 4(b): 3-D graph showing the effect of GG (X1) and XG (X2) for % CDR at 18 h (Y2) 
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Three checkpoint batches were prepared and evaluated for % 
CDR at 2 h and % CDR at 18 h, as shown in table 7. When 
measured % CDR values were compared with predicted % CDR, 
the differences were found to be not significant. Thus, it can be 
concluded that the obtained mathematical equation is valid for 
predicted values [18]. 
 
Table 7: Checkpoint batches with predicted and measured value of %CDR at 2 h and at 18 h 
Batch Code X1 X2 % CDR at 2 h % CDR at 18 h 
Measured Predicted Measured Predicted 
O10 -1 0.5 34.50 35.73 74.04 75.08 
O11 0.5 1 25.22 26.44 68.22 69.43 
O12 0 0.5 24.12 23.24 69.05 70.10 
 
Optimization of formulation 
The overlay plot of responses, generates an optimized area as per 
desired criteria as shown in fig. 5. This was the most important part 
of the response surface methodology. After studying the effect of the 
independent variables on the responses, the levels of these variables 
that give the optimum response were determined. The optimum 
formulation was selected based on the criteria of attaining complete 
and controlled drug release. Batch O1 having 10 mg of GG and 10 mg 
of XG fulfilled maximum requisites of an optimum formulation 
because of better regulation of release rate. The said formulation 
released 33.57 % of the drug in 2 h and 85.62 % in 18 h, however, 
the drug completely got released, i.e. 99.82 % in 24 h, which were in 
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Fig. 5: Overlay plot of optimized batch 
 
Drug release kinetic study 
In order to examine the kinetics of drug release from prepared 
sustained release matrix tablets, the dissolution data of optimized 
formulation O1 were fitted into different kinetic models, i.e. zero 
order, first order, higuchi, hixson-crowell and korsemeyer-peppas 
model. The criteria for the selection of most suitable model were 
the value of regression coefficient (R2) nearer to 1, smallest values 
of SSR and AIC. Table 7 shows the data obtained. The optimized 
formulation fitted well into korsemeyer-peppas, it was confirmed 
the desired release profile. The calculated R2 value for 
korsemeyer-peppas was 0.9882. According to korsemeyer-peppas 
equation, the release exponent “n” value is between 0.45<n<0.89, 
which indicates that the drug release is non-fickian diffusion type 
and states that release followed the diffusion controlled 
mechanism [18]. 
 
Table 8: Fitting of release profile of optimized formulation to kinetic models 
Batch Model Parameters used 
R2 R K SSR AIC 
 Zero-order 0.7756 0.9672 4.745 1705.6322 61.5335 
 First-order 0.9307 0.9738 0.109 526.9088 52.1362 
O1 Higuchi 0.9882 0.9943 19.794 89.5076 37.9546 
 Korsemeyer–Peppas 0.9882 0.9942 19.881 
n=0.498 
89.4736 39.9515 
 Hixson Crowell 0.9149 0.9761 0.029 646.5765 53.7735 
 
Stability study 
Stability study of the sustained release matrix tablet of IB was 
carried out for 6 mo at specified conditions. The stability studies of 
the optimized formulation (O1) shown no significant changes in the 
physical parameters, % drug content and % drug release in 24 h 
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when stored at 40±2 °C/75±5 % RH. So, it was considered that 
formulation having good stability. 
CONCLUSION 
The matrix types of tablets are potential to be an effective sustained 
release drug delivery system over a prolong period of time. The type 
and level of polymer used are important factors that can affect the 
drug release and also the physicochemical properties of this 
sustained release matrix tablets. 32 full factorial design was applied 
to achieve controlled drug release up to 24 h. Among all the 
developed formulations, an O1 formulation which contains the 
mixture of two polymers GG and XG in a proportion of 10 mg each 
gave sustain drug release for 24 h when compared with other 
formulations. So, O1 was selected as the best formulation. The drug 
release kinetics follows korsemeyer-peppas. So, the mechanism was 
found to be non fickian and shows continuous and uniform drug 
release for an extended period of time, an attribute highly desirable 
for any sustained release formulation. The stability studies were 
carried out according to ICH guideline which indicates that the 
selected formulation was stable. From the economical point of view, 
it may be beneficial for the local pharmaceutical firms to adopt such 
simple technologies for the preparation of sustained release 
product. 
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